Volume 94 Issue 46
Issue Date: November 21, 2016
p. 15 ConcentratesIssue Date: November 21, 2016
BMS, Enterome form microbiome pact
Bristol-Myers Squibb will pay Enterome $15 million up front as part of a pact to develop microbiome-derived biomarkers and therapeutics for cancer. The partners will also look for microbiome-derived biomarkers that could indicate whether a patient will benefit from BMS’s immuno-oncology treatments. Given growing evidence that the gut microbiome is involved in how the body responds or grows resistant to cancer immunotherapies, the companies hope to find new targets and therapies that could boost the efficacy of oncology drugs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society
Leave A Comment